umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Adenoviruses 16 and CV23 efficiently transduce human low-passage brain tumor and cancer stem cells
Umeå University, Faculty of Medicine, Clinical Microbiology, Virology.
Umeå University, Faculty of Medicine, Clinical Microbiology, Virology.
Umeå University, Faculty of Medicine, Pharmacology and Clinical Neuroscience, Neurosurgery.
Umeå University, Faculty of Medicine, Clinical Microbiology, Virology.
2007 (English)In: Molecular Therapy, ISSN 1525-0016, E-ISSN 1525-0024, Vol. 15, no 12, 2140-5 p.Article in journal (Refereed) Published
Abstract [en]

Most clinical protocols involving adenovirus (Ad) vectors for gene therapy use a vector based on serotype 5 (Ad5). We believe that this serotype is not suitable for all gene therapy applications and that alternative vectors based on other serotypes should be developed. We have compared the ability of Ad5, Ad11p, Ad16p, and a chimpanzee Ad (CV23) to infect human low-passage brain tumor cells as well as primary glioma cells sorted into a CD133(+) and CD133(-) population. Cancer stem cells have been shown to reside in the CD133(+) population of cells in human glioma tumors and they are of considerable interest in glioma therapy. Ad16p and CV23 infected the low-passage brain tumor cell lines and also the CD133(+) and CD133(-) primary tumor cells most efficiently. Interestingly, as the passage number of the cells increased, the infection capacity of Ad5 increased significantly, whereas this was not seen for CV23. To ensure the therapeutic effect of Ad vectors on brain tumors, the vector must be capable of addressing both the CD133(+) cancer stem cells and the CD133(-) cells of the tumor. In particular, Ad16 and CV23 are meeting this challenge.

Place, publisher, year, edition, pages
2007. Vol. 15, no 12, 2140-5 p.
Identifiers
URN: urn:nbn:se:umu:diva-20693DOI: 10.1038/sj.mt.6300315PubMedID: 17878898OAI: oai:DiVA.org:umu-20693DiVA: diva2:209351
Available from: 2009-03-24 Created: 2009-03-24 Last updated: 2017-12-13

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed
By organisation
VirologyNeurosurgery
In the same journal
Molecular Therapy

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 26 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf